Industry Roundup: Nicotine Exposure ANPR, Athena Petition Denied
This article was originally published in The Tan Sheet
Executive Summary
Comments sought for nicotine-exposure ANPR; Supreme Court denies Athena petition; Neuragen U.S. market rights; Prestige ‘TMI’ about Monistat; and more news in brief.
You may also be interested in...
Athena Appeal Decision Could Open ‘Floodgate’ For False Claims Litigation
Lower court decisions that Athena Cosmetics’ RevitaLash products is an unapproved drug competing unfairly against Allergan's Latisse drug could have broader implications if the Supreme Court denies the firm's request for review. Already beleaguered by class actions following FDA warnings, firms could face more opportunistic lawsuits if federal courts are left to determine a product's intended use and regulatory status.
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.